Spondyloarthritis: How far are we from precision medicine?
Spondyloarthritis (SpA) is a family of heterogenous diseases consisting of different phenotypes. The exact disease mechanism remains unclear but evidence shows the complex pathophysiology with interplay between genome, microbiome, and immunome. Biologic DMARDs have markedly improved patients' d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.988532/full |
| _version_ | 1798002076252372992 |
|---|---|
| author | Jacqueline So Ann-Sophie De Craemer Ann-Sophie De Craemer Dirk Elewaut Dirk Elewaut Lai-Shan Tam |
| author_facet | Jacqueline So Ann-Sophie De Craemer Ann-Sophie De Craemer Dirk Elewaut Dirk Elewaut Lai-Shan Tam |
| author_sort | Jacqueline So |
| collection | DOAJ |
| description | Spondyloarthritis (SpA) is a family of heterogenous diseases consisting of different phenotypes. The exact disease mechanism remains unclear but evidence shows the complex pathophysiology with interplay between genome, microbiome, and immunome. Biologic DMARDs have markedly improved patients' disease control and quality of life. However, treatment response varies among patients. There is a growing need to identify biomarkers for the diagnosis, prognosis, prevention, and treatment of SpA. Genomic studies have been the research focus in the past two decades and have identified important genes involved in SpA. In recent years, emerging evidence supports the link between gut and joint inflammation in SpA, in which the role of gut microbiome in SpA is of great interest. Herein, potential genetic and gut microbial biomarkers for predicting treatment response are discussed. Novel strategies targeting dysbiosis in SpA are also summarized. These results represent a significant step toward precision medicine for patients with SpA. |
| first_indexed | 2024-04-11T11:46:28Z |
| format | Article |
| id | doaj.art-4e286b7d9100496f8571649900929fe6 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-11T11:46:28Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-4e286b7d9100496f8571649900929fe62022-12-22T04:25:32ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-09-01910.3389/fmed.2022.988532988532Spondyloarthritis: How far are we from precision medicine?Jacqueline So0Ann-Sophie De Craemer1Ann-Sophie De Craemer2Dirk Elewaut3Dirk Elewaut4Lai-Shan Tam5Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong SAR, ChinaDivision of Rheumatology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, BelgiumCenter for Inflammation Research, VIB-UGent, Zwijnaarde, BelgiumDivision of Rheumatology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, BelgiumCenter for Inflammation Research, VIB-UGent, Zwijnaarde, BelgiumDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSpondyloarthritis (SpA) is a family of heterogenous diseases consisting of different phenotypes. The exact disease mechanism remains unclear but evidence shows the complex pathophysiology with interplay between genome, microbiome, and immunome. Biologic DMARDs have markedly improved patients' disease control and quality of life. However, treatment response varies among patients. There is a growing need to identify biomarkers for the diagnosis, prognosis, prevention, and treatment of SpA. Genomic studies have been the research focus in the past two decades and have identified important genes involved in SpA. In recent years, emerging evidence supports the link between gut and joint inflammation in SpA, in which the role of gut microbiome in SpA is of great interest. Herein, potential genetic and gut microbial biomarkers for predicting treatment response are discussed. Novel strategies targeting dysbiosis in SpA are also summarized. These results represent a significant step toward precision medicine for patients with SpA.https://www.frontiersin.org/articles/10.3389/fmed.2022.988532/fullspondyloarthritis precision medicinegeneticsmicrobiomemetabolomicsspondyloarthritis |
| spellingShingle | Jacqueline So Ann-Sophie De Craemer Ann-Sophie De Craemer Dirk Elewaut Dirk Elewaut Lai-Shan Tam Spondyloarthritis: How far are we from precision medicine? Frontiers in Medicine spondyloarthritis precision medicine genetics microbiome metabolomics spondyloarthritis |
| title | Spondyloarthritis: How far are we from precision medicine? |
| title_full | Spondyloarthritis: How far are we from precision medicine? |
| title_fullStr | Spondyloarthritis: How far are we from precision medicine? |
| title_full_unstemmed | Spondyloarthritis: How far are we from precision medicine? |
| title_short | Spondyloarthritis: How far are we from precision medicine? |
| title_sort | spondyloarthritis how far are we from precision medicine |
| topic | spondyloarthritis precision medicine genetics microbiome metabolomics spondyloarthritis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.988532/full |
| work_keys_str_mv | AT jacquelineso spondyloarthritishowfararewefromprecisionmedicine AT annsophiedecraemer spondyloarthritishowfararewefromprecisionmedicine AT annsophiedecraemer spondyloarthritishowfararewefromprecisionmedicine AT dirkelewaut spondyloarthritishowfararewefromprecisionmedicine AT dirkelewaut spondyloarthritishowfararewefromprecisionmedicine AT laishantam spondyloarthritishowfararewefromprecisionmedicine |